Is Jaypirca now a first-line pill for CLL and SLL?
Yes. On October 2, 2026 the FDA approved pirtobrutinib (Jaypirca) as a first-line daily pill for adults with newly diagnosed CLL or SLL, as long as the cancer doesn't carry a 17p chromosome deletion. In the trial behind the approval, pirtobrutinib cut the risk of progression or death by about four-fifths compared with chemotherapy. A separate head-to-head found it both more effective and gentler on the heart than ibrutinib. The catch: no trial has yet tested it against the two second-generation BTK pills most oncologists reach for first.
The dose is 200 mg once a day, continued until the disease progresses or you can't tolerate the drug. Pirtobrutinib binds Bruton tyrosine kinase (BTK) reversibly rather than locking onto it, so it keeps working after a cancer picks up the C481 mutation that disables ibrutinib, acalabrutinib, and zanubrutinib. That design is why it was originally cleared for patients who had already failed one of those. What's new is that it has moved to the front of the line, for everyone except the 5 to 8% of newly diagnosed patients whose cancer carries a 17p deletion.
What the approval trial showed
The approval rests on BRUIN CLL-313, a 282-patient randomized trial pitting pirtobrutinib against bendamustine plus rituximab, a standard chemotherapy regimen. The benefit held in the subgroups that usually fare worst on chemotherapy: unmutated IGHV, complex karyotype, and TP53 mutations. If you've been quoted a grim prognosis because of one of those features, this is the trial to look at.
How it compares to the pills oncologists already use
Only one head-to-head has been run so far. In BRUIN CLL-314, pirtobrutinib was tested against ibrutinib in untreated patients. Early progression-free survival favored it, and rates of atrial fibrillation and high blood pressure were both lower. There's no randomized trial yet against acalabrutinib or zanubrutinib, which have already been shown to be safer than ibrutinib. Indirect network comparisons hint pirtobrutinib may be at least as effective, but the ranges overlap too much to call a winner.
| Drug | How it binds BTK | First-line trial evidence | Atrial fibrillation signal |
|---|---|---|---|
| Pirtobrutinib (Jaypirca) | Reversible, non-covalent | Beat chemotherapy (BRUIN CLL-313); more effective than ibrutinib (BRUIN CLL-314) | Low; roughly 2 to 3% in trials |
| Ibrutinib (Imbruvica) | Irreversible; attaches to C481 | Approved after beating chemotherapy in older trials | Highest; roughly 8 to 16% across registration trials |
| Acalabrutinib (Calquence) | Irreversible; attaches to C481 | Approved for frontline CLL | Lower than ibrutinib |
| Zanubrutinib (Brukinsa) | Irreversible; attaches to C481 | Approved for frontline CLL | Lower than ibrutinib |
Who the label leaves out
The frontline indication specifically excludes anyone with a known 17p deletion. That's the small, highest-risk slice of newly diagnosed CLL, and the trial simply did not test pirtobrutinib there. If a 17p deletion shows up on your FISH panel, acalabrutinib, zanubrutinib, or a venetoclax-based regimen are the better-studied options. Confirm your FISH and TP53 status before you pick a frontline drug; both change what you should take.
Side effects
Most were common but manageable. In BRUIN CLL-313, upper respiratory infections hit about 27% of patients, rash 22%, and COVID-19 21%. Serious adverse events of any kind happened in 28%. Label warnings include infections, bleeding, low blood counts, cardiac arrhythmias, second cancers, and liver injury. The cardiac signal is low compared with ibrutinib, but the drug isn't a free pass. Cytopenias and infection risk still warrant monitoring over time.
What it costs
The U.S. list price runs around $21,000 for a 30-day supply, and therapy continues until the disease progresses. That number is intimidating. Medicare beneficiaries can't use manufacturer copay cards under federal rules, but foundation grants and patient assistance programs still apply. Run the numbers for your own coverage before you assume the drug is out of reach.
How to think about the news
Pirtobrutinib's move to the front line is a step forward for most newly diagnosed CLL and SLL: stronger disease control than chemotherapy, less heart toxicity than ibrutinib, and a daily pill instead of an infusion. For now it joins the shortlist of first-line options rather than replacing acalabrutinib or zanubrutinib, because no trial has pitted them against each other. Three things would settle that: a randomized trial against a second-generation covalent inhibitor, longer survival data from the trials in follow-up, and a label that includes patients with a 17p deletion.